The cell-free dna (cfdna) blood collection tube market size has grown rapidly in recent years. It will grow from $1.33 billion in 2025 to $1.51 billion in 2026 at a compound annual growth rate (CAGR) of 13.6%. The growth in the historic period can be attributed to increasing demand for prenatal testing, growing cancer diagnostics, adoption of cfDNA in research, rising laboratory automation, expansion of diagnostic centers.
The cell-free dna (cfdna) blood collection tube market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to innovation in blood tube preservatives, integration with AI diagnostics, growing liquid biopsy market, expansion of clinical trials, rising demand in emerging markets. Major trends in the forecast period include enhanced sample preservation, integration with liquid biopsy platforms, standardized blood collection protocols, automation in sample processing, high-stability tube designs.
The rising prevalence of respiratory disorders is expected to drive the growth of the cell-free DNA (cfDNA) blood collection tube market in the coming years. Respiratory disorders are conditions that impact the lungs and other parts of the respiratory system, making it difficult to breathe properly and affecting the delivery of oxygen to the blood or removal of carbon dioxide from the body. The growing prevalence of respiratory disorders is largely attributed to air pollution, which irritates the airways, decreases lung function, and heightens the risk of conditions such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Cell-free DNA (cfDNA) blood collection tubes play a crucial role in managing respiratory disorders by detecting genetic mutations, tracking disease progression, and assessing treatment effectiveness with a simple blood test, reducing the need for invasive lung biopsies. For instance, in December 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that between October 1 and November 30, 2024, respiratory syncytial virus (RSV) led to an estimated 17,000 to 34,000 hospitalizations. Thus, the increasing occurrence of respiratory disorders is fueling the demand for cfDNA blood collection tubes.
The rising incidence of cancer is expected to drive growth in the cell-free DNA (cfDNA) blood collection tube market in the future. The growing number of cancer cases is linked to lifestyle factors such as poor diet, smoking, and lack of physical activity. cfDNA blood collection tubes are increasingly used in cancer care for liquid biopsies, which allow for the detection of tumor-specific genetic mutations, monitoring of disease progression, evaluation of treatment responses, and identification of resistance mutations through a simple blood test. This method reduces the need for invasive tissue biopsies. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, projected that the number of cancer survivors in the U.S. would rise to 26 million by 2040, up from 18.1 million in 2022. Therefore, the growing incidence of cancer is driving the demand for cfDNA blood collection tubes.
Key companies operating in the cfDNA blood collection tube market are focusing on automating cfDNA extraction to improve workflow efficiency. Automation of cfDNA extraction involves the use of advanced robotic systems and standardized procedures to isolate cell-free DNA from blood samples with minimal manual intervention, enhancing efficiency, accuracy, and consistency while reducing turnaround times and human error. For example, in September 2023, Yourgene Health plc, a molecular diagnostics company based in the UK, introduced the MagBench Automated DNA Extraction Instrument and Kit. This solution provides a fast, simple, and cost-effective bench-top robotic option optimized for cfDNA extraction in non-invasive prenatal testing (NIPT) workflows. The launch aims to enhance automation in NIPT workflows, delivering higher throughput, reproducibility, and reliability in cfDNA extraction while reducing hands-on time and operational expenses.
Major companies operating in the cell-free dna (cfdna) blood collection tube market are Roche Holding AG, Thermo Fisher Scientific Inc., Becton Dickinson (BD), Qiagen N.V., SARSTEDT AG & Co. KG, Guangzhou Improve Medical Technology, Streck Inc., DiaCarta Inc., Zymo Research Corporation, Biomatrica Inc., PreAnalytiX GmbH, Beijing Cowin Bioscience Co.Ltd., Norgen Biotek Corporation, Nonacus Limited, Guangdong Ardent Biomed Co. Ltd, MagBio Genomics Inc., VanGenes, BEAVER, Hebei Xinle Science & Technology Co. Ltd., Nasmed Diagnostics Pvt. Ltd.
North America was the largest region in the cell-free DNA (cfDNA) blood collection tube market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell-free dna (cfdna) blood collection tube market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell-free dna (cfdna) blood collection tube market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cfDNA blood collection tube market by increasing the cost of imported tubes and reagents, particularly in regions such as europe and asia-pacific. Hospitals, diagnostic labs, and research institutions are most affected. However, tariffs encourage development of locally manufactured tubes with improved preservation features, which may reduce dependency on imports and promote market growth.
The cell-free dna (cfdna) blood collection tube market research report is one of a series of new reports that provides cell-free dna (cfdna) blood collection tube market statistics, including cell-free dna (cfdna) blood collection tube industry global market size, regional shares, competitors with a cell-free dna (cfdna) blood collection tube market share, detailed cell-free dna (cfdna) blood collection tube market segments, market trends and opportunities, and any further data you may need to thrive in the cell-free dna (cfdna) blood collection tube industry. This cell-free dna (cfdna) blood collection tube market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A cell-free DNA (cfDNA) blood collection tube is a specialized device designed to collect, stabilize, and transport blood samples for cfDNA analysis. It contains preservatives that protect nucleic acids from degradation and minimize the release of genomic DNA from white blood cells. These tubes support accurate and reliable results in downstream applications such as liquid biopsy, prenatal testing, and cancer diagnostics.
The primary types in the cell-free DNA (cfDNA) blood collection tube market are 5 mL and 10 mL. The 5 mL cfDNA blood collection tube is a smaller-volume option commonly used for individual or routine sample collection. Sample types include plasma, serum, and whole blood. Applications cover in vitro diagnostics and scientific research. Key end-users include diagnostic laboratories, hospitals and clinical centers, genetic diagnostic labs, cancer research centers, research and development institutions, and conventional diagnostic facilities.
The cell-free DNA (cfDNA) blood collection tube market consists of sales of plasma separation tubes, cryogenic storage systems, and plasma prep centrifugation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cell-free dna (cfdna) blood collection tube market size is expected to see rapid growth in the next few years. It will grow to $2.49 billion in 2030 at a compound annual growth rate (CAGR) of 13.3%. The growth in the forecast period can be attributed to innovation in blood tube preservatives, integration with AI diagnostics, growing liquid biopsy market, expansion of clinical trials, rising demand in emerging markets. Major trends in the forecast period include enhanced sample preservation, integration with liquid biopsy platforms, standardized blood collection protocols, automation in sample processing, high-stability tube designs.
The rising prevalence of respiratory disorders is expected to drive the growth of the cell-free DNA (cfDNA) blood collection tube market in the coming years. Respiratory disorders are conditions that impact the lungs and other parts of the respiratory system, making it difficult to breathe properly and affecting the delivery of oxygen to the blood or removal of carbon dioxide from the body. The growing prevalence of respiratory disorders is largely attributed to air pollution, which irritates the airways, decreases lung function, and heightens the risk of conditions such as asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Cell-free DNA (cfDNA) blood collection tubes play a crucial role in managing respiratory disorders by detecting genetic mutations, tracking disease progression, and assessing treatment effectiveness with a simple blood test, reducing the need for invasive lung biopsies. For instance, in December 2024, the Centers for Disease Control and Prevention (CDC), a U.S.-based government agency, reported that between October 1 and November 30, 2024, respiratory syncytial virus (RSV) led to an estimated 17,000 to 34,000 hospitalizations. Thus, the increasing occurrence of respiratory disorders is fueling the demand for cfDNA blood collection tubes.
The rising incidence of cancer is expected to drive growth in the cell-free DNA (cfDNA) blood collection tube market in the future. The growing number of cancer cases is linked to lifestyle factors such as poor diet, smoking, and lack of physical activity. cfDNA blood collection tubes are increasingly used in cancer care for liquid biopsies, which allow for the detection of tumor-specific genetic mutations, monitoring of disease progression, evaluation of treatment responses, and identification of resistance mutations through a simple blood test. This method reduces the need for invasive tissue biopsies. For example, in May 2024, the National Cancer Institute, a U.S.-based government agency, projected that the number of cancer survivors in the U.S. would rise to 26 million by 2040, up from 18.1 million in 2022. Therefore, the growing incidence of cancer is driving the demand for cfDNA blood collection tubes.
Key companies operating in the cfDNA blood collection tube market are focusing on automating cfDNA extraction to improve workflow efficiency. Automation of cfDNA extraction involves the use of advanced robotic systems and standardized procedures to isolate cell-free DNA from blood samples with minimal manual intervention, enhancing efficiency, accuracy, and consistency while reducing turnaround times and human error. For example, in September 2023, Yourgene Health plc, a molecular diagnostics company based in the UK, introduced the MagBench Automated DNA Extraction Instrument and Kit. This solution provides a fast, simple, and cost-effective bench-top robotic option optimized for cfDNA extraction in non-invasive prenatal testing (NIPT) workflows. The launch aims to enhance automation in NIPT workflows, delivering higher throughput, reproducibility, and reliability in cfDNA extraction while reducing hands-on time and operational expenses.
Major companies operating in the cell-free dna (cfdna) blood collection tube market are Roche Holding AG, Thermo Fisher Scientific Inc., Becton Dickinson (BD), Qiagen N.V., SARSTEDT AG & Co. KG, Guangzhou Improve Medical Technology, Streck Inc., DiaCarta Inc., Zymo Research Corporation, Biomatrica Inc., PreAnalytiX GmbH, Beijing Cowin Bioscience Co.Ltd., Norgen Biotek Corporation, Nonacus Limited, Guangdong Ardent Biomed Co. Ltd, MagBio Genomics Inc., VanGenes, BEAVER, Hebei Xinle Science & Technology Co. Ltd., Nasmed Diagnostics Pvt. Ltd.
North America was the largest region in the cell-free DNA (cfDNA) blood collection tube market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell-free dna (cfdna) blood collection tube market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cell-free dna (cfdna) blood collection tube market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cfDNA blood collection tube market by increasing the cost of imported tubes and reagents, particularly in regions such as europe and asia-pacific. Hospitals, diagnostic labs, and research institutions are most affected. However, tariffs encourage development of locally manufactured tubes with improved preservation features, which may reduce dependency on imports and promote market growth.
The cell-free dna (cfdna) blood collection tube market research report is one of a series of new reports that provides cell-free dna (cfdna) blood collection tube market statistics, including cell-free dna (cfdna) blood collection tube industry global market size, regional shares, competitors with a cell-free dna (cfdna) blood collection tube market share, detailed cell-free dna (cfdna) blood collection tube market segments, market trends and opportunities, and any further data you may need to thrive in the cell-free dna (cfdna) blood collection tube industry. This cell-free dna (cfdna) blood collection tube market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
A cell-free DNA (cfDNA) blood collection tube is a specialized device designed to collect, stabilize, and transport blood samples for cfDNA analysis. It contains preservatives that protect nucleic acids from degradation and minimize the release of genomic DNA from white blood cells. These tubes support accurate and reliable results in downstream applications such as liquid biopsy, prenatal testing, and cancer diagnostics.
The primary types in the cell-free DNA (cfDNA) blood collection tube market are 5 mL and 10 mL. The 5 mL cfDNA blood collection tube is a smaller-volume option commonly used for individual or routine sample collection. Sample types include plasma, serum, and whole blood. Applications cover in vitro diagnostics and scientific research. Key end-users include diagnostic laboratories, hospitals and clinical centers, genetic diagnostic labs, cancer research centers, research and development institutions, and conventional diagnostic facilities.
The cell-free DNA (cfDNA) blood collection tube market consists of sales of plasma separation tubes, cryogenic storage systems, and plasma prep centrifugation systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cell-Free DNA (cfDNA) Blood Collection Tube Market Characteristics
3. Cell-Free DNA (cfDNA) Blood Collection Tube Market Supply Chain Analysis
4. Global Cell-Free DNA (cfDNA) Blood Collection Tube Market Trends and Strategies
5. Cell-Free DNA (cfDNA) Blood Collection Tube Market Analysis of End Use Industries
7. Global Cell-Free DNA (cfDNA) Blood Collection Tube Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cell-Free DNA (cfDNA) Blood Collection Tube Total Addressable Market (TAM) Analysis for the Market
9. Cell-Free DNA (cfDNA) Blood Collection Tube Market Segmentation
10. Cell-Free DNA (cfDNA) Blood Collection Tube Market Regional and Country Analysis
11. Asia-Pacific Cell-Free DNA (cfDNA) Blood Collection Tube Market
12. China Cell-Free DNA (cfDNA) Blood Collection Tube Market
13. India Cell-Free DNA (cfDNA) Blood Collection Tube Market
14. Japan Cell-Free DNA (cfDNA) Blood Collection Tube Market
15. Australia Cell-Free DNA (cfDNA) Blood Collection Tube Market
16. Indonesia Cell-Free DNA (cfDNA) Blood Collection Tube Market
17. South Korea Cell-Free DNA (cfDNA) Blood Collection Tube Market
18. Taiwan Cell-Free DNA (cfDNA) Blood Collection Tube Market
19. South East Asia Cell-Free DNA (cfDNA) Blood Collection Tube Market
20. Western Europe Cell-Free DNA (cfDNA) Blood Collection Tube Market
21. UK Cell-Free DNA (cfDNA) Blood Collection Tube Market
22. Germany Cell-Free DNA (cfDNA) Blood Collection Tube Market
23. France Cell-Free DNA (cfDNA) Blood Collection Tube Market
24. Italy Cell-Free DNA (cfDNA) Blood Collection Tube Market
25. Spain Cell-Free DNA (cfDNA) Blood Collection Tube Market
26. Eastern Europe Cell-Free DNA (cfDNA) Blood Collection Tube Market
27. Russia Cell-Free DNA (cfDNA) Blood Collection Tube Market
28. North America Cell-Free DNA (cfDNA) Blood Collection Tube Market
29. USA Cell-Free DNA (cfDNA) Blood Collection Tube Market
30. Canada Cell-Free DNA (cfDNA) Blood Collection Tube Market
31. South America Cell-Free DNA (cfDNA) Blood Collection Tube Market
32. Brazil Cell-Free DNA (cfDNA) Blood Collection Tube Market
33. Middle East Cell-Free DNA (cfDNA) Blood Collection Tube Market
34. Africa Cell-Free DNA (cfDNA) Blood Collection Tube Market
36. Cell-Free DNA (cfDNA) Blood Collection Tube Market Competitive Landscape and Company Profiles
37. Cell-Free DNA (cfDNA) Blood Collection Tube Market Other Major and Innovative Companies
40. Cell-Free DNA (cfDNA) Blood Collection Tube Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cell-Free DNA (cfDNA) Blood Collection Tube Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cell-free dna (cfdna) blood collection tube market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cell-free dna (cfdna) blood collection tube? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cell-free dna (cfdna) blood collection tube market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: 5ml; 10ml2) By Sample Type: Plasma; Serum; Whole Blood
3) By Application: In Vitro Diagnostics; Scientific Research
4) By End-User: Diagnostic Laboratories; Hospitals Or Clinical Centers; Genetic Diagnostic Labs; Cancer Research Centers; Research And Development Institutions; Conventional Diagnostic Centers
Subsegments:
1) By 5 mL: Single Use Tube; Vacuum Blood Collection Tube; Gel Separator Tube2) By 10 mL: Double Draw Tube; High Volume Collection Tube; Anticoagulant Treated Tube
Companies Mentioned: Roche Holding AG; Thermo Fisher Scientific Inc.; Becton Dickinson (BD); Qiagen N.V.; SARSTEDT AG & Co. KG; Guangzhou Improve Medical Technology; Streck Inc.; DiaCarta Inc.; Zymo Research Corporation; Biomatrica Inc.; PreAnalytiX GmbH; Beijing Cowin Bioscience Co.Ltd.; Norgen Biotek Corporation; Nonacus Limited; Guangdong Ardent Biomed Co. Ltd; MagBio Genomics Inc.; VanGenes; BEAVER; Hebei Xinle Science & Technology Co. Ltd.; Nasmed Diagnostics Pvt. Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cell-Free DNA (cfDNA) Blood Collection Tube market report include:- Roche Holding AG
- Thermo Fisher Scientific Inc.
- Becton Dickinson (BD)
- Qiagen N.V.
- SARSTEDT AG & Co. KG
- Guangzhou Improve Medical Technology
- Streck Inc.
- DiaCarta Inc.
- Zymo Research Corporation
- Biomatrica Inc.
- PreAnalytiX GmbH
- Beijing Cowin Bioscience Co.Ltd.
- Norgen Biotek Corporation
- Nonacus Limited
- Guangdong Ardent Biomed Co. Ltd
- MagBio Genomics Inc.
- VanGenes
- BEAVER
- Hebei Xinle Science & Technology Co. Ltd.
- Nasmed Diagnostics Pvt. Ltd.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.51 Billion |
| Forecasted Market Value ( USD | $ 2.49 Billion |
| Compound Annual Growth Rate | 13.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
